Immunotherapy of Melanoma
Samenvatting
This book focusses on the different types of immunotherapeutics that are currently being used and developed for the treatment of melanoma. In recent years, immunotherapy has revolutionized the treatment of metastatic melanoma and other types of cancer.
Discussing treatment options for melanoma and the success of immunotherapy along with the challenges of immunotherapy, this book covers epidemiology, susceptibility genes, and treatment recommendations from Society for Immunotherapy of Cancer, as well as immune based therapies such as aldesleukin, Intron-A, Sylatron, Yervoy, Opdivo, Keytruda, Imlygic, DC vaccines and adoptive cell therapy. The detailed information included on the key immune cells involved in anti-tumor immune response and immune-inhibitory mechanisms in tumor microenvironment will aid the understanding of tumor immunology. Both academic as well as industry-based researchers, developing novel anti-cancer therapies, will also benefit from the details of promising molecular targets and immunotherapeutic strategies under investigation.
With 132 illustrations including synopsis tables for important information, over 1200 references (majority of which are openly accessible) and details of more than 150 ongoing clinical trials, this book is a valuable source of information for health care providers as well as cancer biologists interested in learning about melanoma and the significant advances made by immunotherapy.
Specificaties
Inhoudsopgave
<p>1. Melanoma</p>
<p> 1.1 Introduction, history and epidemiology</p>
<p> 1.2 Diagnosis, subtypes and staging</p>
<p> 1.3 Etiology</p>
1.4 Treatment</p>
<p>2. Tumor immunology</p>
<p> 2.1 Overview of immune system</p>
<p> 2.2 Dendritic cells</p>
<p> 2.3 T-cells</p>
2.4 Mechanisms of immune evasion by cancer</p>
<p>3. Immune based drugs approved for treatment of melanoma< <p> 3.1 IFN-α2b</p>
<p> 3.2 IL-2</p>
<p> 3.3 Ipilimumab</p>
3.4 Nivolumab</p>
<p> 3.5 Pembrolizumab</p>
<p> 3.6 Talimogene laherparepvec</p>
<p>4. Promising immunotherapeutic approaches in clinical trials</p>
<p> 4.1 Introduction</p>
4.2 Monoclonal antibodies</p>
<p> 4.3 Cytokines</p>
<p> 4.4 Cancer vaccines</p>
p; 4.5 Dendritic cells</p>
<p> 4.6 Adoptive cell therapy</p>
<p>5. Challenges of immunotherapy</p><br></p><p>Index</p>